Geode Capital Management LLC Purchases 53,879 Shares of CEL-SCI Co. (NYSE:CVM)

Geode Capital Management LLC grew its position in CEL-SCI Co. (NYSE:CVM) by 9.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 612,861 shares of the company’s stock after purchasing an additional 53,879 shares during the quarter. Geode Capital Management LLC owned approximately 0.96% of CEL-SCI worth $650,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Calton & Associates Inc. bought a new position in shares of CEL-SCI in the third quarter valued at approximately $50,000. Black Diamond Financial LLC increased its position in CEL-SCI by 35.8% during the second quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock worth $84,000 after acquiring an additional 19,000 shares during the period. Plotkin Financial Advisors LLC bought a new position in CEL-SCI during the third quarter worth $98,000. Thoroughbred Financial Services LLC increased its position in CEL-SCI by 140.9% during the second quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after acquiring an additional 80,001 shares during the period. Finally, Renaissance Technologies LLC increased its position in CEL-SCI by 29.9% during the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after acquiring an additional 40,000 shares during the period. Institutional investors own 12.08% of the company’s stock.

CEL-SCI Trading Up 16.0 %

Shares of CVM stock opened at $0.43 on Friday. CEL-SCI Co. has a 1 year low of $0.36 and a 1 year high of $3.08. The firm’s fifty day simple moving average is $0.61 and its 200 day simple moving average is $0.94. The firm has a market capitalization of $31.46 million, a P/E ratio of -0.73 and a beta of 0.65. The company has a current ratio of 0.64, a quick ratio of 0.18 and a debt-to-equity ratio of 1.00.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of CEL-SCI in a research report on Wednesday. They set a “sell” rating on the stock.

CEL-SCI Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.